Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd. > TWO Insiders bought shares TODAY ! Interesting next week !!
View:
Comment by 1ottrunner on Sep 04, 2021 7:27am
If there was some news coming that they know about, THEY CANT BUY!!!   They are simply trying to keep the SP afloat while they hunt for financing.  
Comment by Billy111 on Sep 04, 2021 9:17am
Exactly, what is the legal time frame again?
Comment by kh231 on Sep 04, 2021 8:28pm
Indeed! Get ready to BLAST-OFF!!  Those insiders bought at and below 41cents. They know good news is coming. RVV will be the sleeper of the year, a 10-bagger at $4. No guff!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities